Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 3/20 | 0.70 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.70 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.53 |
| ▸ | HTR3B | O95264 | 1/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Itasetron SCHEMBL18311459 | 1.00 | HTR3A (0.70) | HTR3AHTR4TMEM97SIGMAR1HTR3E | |
| Itasetron SCHEMBL1821834 | 1.00 | HTR3A (0.70) | HTR3AHTR4TMEM97SIGMAR1HTR3E | |
| Itasetron SCHEMBL62124 | 1.00 | HTR3A (0.70) | HTR3AHTR4TMEM97SIGMAR1HTR3E | |
| Itasetron SCHEMBL31406725 | 1.00 | HTR3A (0.70) | HTR3AHTR4TMEM97SIGMAR1HTR3E | |
| Itasetron SCHEMBL7342367 | 0.99 | HTR3A (0.69) | HTR3AHTR4TMEM97SIGMAR1HTR3E | |
| Itasetron SCHEMBL4828092 | 0.99 | HTR3A (0.69) | HTR3AHTR4TMEM97SIGMAR1HTR3E | |
| Itasetron SCHEMBL4828089 | 0.99 | HTR3A (0.69) | HTR3AHTR4TMEM97SIGMAR1HTR3E | |
| Itasetron SCHEMBL8720455 | 0.98 | HTR3A (0.67) | HTR3AHTR4TMEM97SIGMAR1HTR3E | |
| Itasetron SCHEMBL1651310 | 0.98 | HTR3A (0.67) | HTR3AHTR4TMEM97SIGMAR1HTR3E | |
| Itasetron SCHEMBL7107757 | 0.97 | HTR3A (0.66) | HTR3AHTR4TMEM97SIGMAR1HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8052 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| US-11547700-B2 | Compositions and methods for treating synucleinopathies | CHASE THERAPEUTICS CORPORATION (US) | 2023-01-10 | — | — | US | claimed |
| US-11345956-B2 | Methods and compositions related to prostate cancer therapeutics | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-31 | — | — | US | claimed |
| US-11207289-B2 | Use of benzofuran lignans to induce IL-25 expression and suppress mammary tumor metastasis | ACADEMIA SINICA (TW) | 2021-12-28 | — | — | US | claimed |
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | AMUNIX PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | claimed |
| US-20210060040-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | claimed |
| EP-3191114-B1 | OCCIDIOFUNGIN FORMULATIONS AND USES THEREOF | UNIV MISSISSIPPI STATE (US) | 2021-03-03 | — | — | EP | claimed |
| US-20200289454-A1 | USE OF BENZOFURAN LIGNANS TO INDUCE IL-25 EXPRESSION AND SUPPRESS MAMMARY TUMOR METASTASIS | Yang, Ning-Sun (TW) | 2020-09-17 | — | — | US | claimed |
| WO-1999064046-A1 | MULTIVALENT AGONISTS, PARTIAL AGONISTS, INVERSE AGONISTS AND ANTAGONISTS OF THE 5-HT3 RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| WO-1999017755-A2 | MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 1999-04-15 | — | — | WO | claimed |
| WO-1998047481-A1 | USE OF 5HT3 ANTAGONISTS FOR PROMOTING INTESTINAL LAVAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-10-29 | — | — | WO | claimed |
| US-5552408-A | Benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists | BOEHRINGER INGELHEIM ITALIA S.P.A. (IT) | 1996-09-03 | — | — | US | claimed |
| EP-0523013-B1 | Use of benzimidazoline-2-oxo-1-carboxylic acid derivatives in the treatment of organic mental diseases | BOEHRINGER INGELHEIM ITALIA (IT) | 1994-12-21 | — | — | EP | claimed |
| US-5358954-A | Antiserotonine agent, antiemetic, gastrointestinal disorders | BOEHRINGER INGELHEIM ITALIA (IT) | 1994-10-25 | — | — | US | claimed |
| EP-0309423-B1 | New benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists | BOEHRINGER INGELHEIM ITALIA (IT) | 1994-06-15 | — | — | EP | claimed |
| US-5223511-A | Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists | BOEHRINGER INGELHEIM ITALIA S.P.A. (IT) | 1993-06-29 | — | — | US | claimed |
| EP-0523013-A2 | Use of benzimidazoline-2-oxo-1-carboxylic acid derivatives in the treatment of organic mental diseases | BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) | 1993-01-13 | — | — | EP | claimed |
| EP-0309423-A2 | New benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists | BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) | 1989-03-29 | — | — | EP | claimed |